- Home
- TNGX vs NCZ Comparison
TNGX vs NCZ Comparison
Compare TNGX & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NCZ
- Stock Information
- Founded
- TNGX 2014
- NCZ 2003
- Country
- TNGX United States
- NCZ United States
- Employees
- TNGX N/A
- NCZ N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- TNGX Health Care
- NCZ Finance
- Exchange
- TNGX Nasdaq
- NCZ Nasdaq
- Market Cap
- TNGX 735.0M
- NCZ 240.5M
- IPO Year
- TNGX N/A
- NCZ N/A
- Fundamental
- Price
- TNGX $6.64
- NCZ $3.17
- Analyst Decision
- TNGX Strong Buy
- NCZ
- Analyst Count
- TNGX 8
- NCZ 0
- Target Price
- TNGX $15.14
- NCZ N/A
- AVG Volume (30 Days)
- TNGX 885.7K
- NCZ 533.0K
- Earning Date
- TNGX 11-06-2024
- NCZ 01-01-0001
- Dividend Yield
- TNGX N/A
- NCZ 12.16%
- EPS Growth
- TNGX N/A
- NCZ N/A
- EPS
- TNGX N/A
- NCZ N/A
- Revenue
- TNGX $42,509,000.00
- NCZ N/A
- Revenue This Year
- TNGX $18.15
- NCZ N/A
- Revenue Next Year
- TNGX N/A
- NCZ N/A
- P/E Ratio
- TNGX N/A
- NCZ N/A
- Revenue Growth
- TNGX 26.16
- NCZ N/A
- 52 Week Low
- TNGX $6.33
- NCZ $2.50
- 52 Week High
- TNGX $13.01
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- TNGX 37.15
- NCZ 58.66
- Support Level
- TNGX $6.83
- NCZ $3.14
- Resistance Level
- TNGX $7.47
- NCZ $3.22
- Average True Range (ATR)
- TNGX 0.37
- NCZ 0.05
- MACD
- TNGX 0.11
- NCZ -0.00
- Stochastic Oscillator
- TNGX 27.31
- NCZ 59.37
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas and consumable fuels and others.